Evidence map›Paper›PMID 1752782›Full record

ArticleJapanese journal of cancer research : Gann1991

Activation and suppression of a cryptic promoter in the intron of the human melanoma-associated ME491 antigen gene.

N Takahashi, H Hotta, M Homma

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Japanese journal of cancer research : Gann, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

N TakahashiDepartment of Microbiology, Kobe University School of Medicine.
H Hotta
M Homma
Kobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A deletion mutant of the human melanoma-associated ME491 antigen gene starting at the first intron (lambda R31) differentially mediates the antigen expression depending on the cell type. Cryptic promoter activity residing in a 270-base-pair (bp) fragment of the first intron was examined by primer extension analysis and recombinant chloramphenicol acetyltransferase (CAT) assay. The cryptic promoter, further localized within a 153-bp fragment (fr153BN), exerted its effect in Ltk- and H-ras-transformed NIH3T3 (3T3-Hras) but not in parental NIH3T3 cells. The results suggested that the cryptic promoter was associated with a novel ras-responsive positive regulatory element, since fr153BN did not contain an AP-1-binding sequence motif, known as the ras-responsive enhancer element. The cryptic promoter activity of fr153BN was suppressed by an upstream 121-bp fragment (fr121SB) which contained a consensus sequence motif for binding of a repressor protein, GC factor, and regions showing sequence similarity with putative cis-acting repressor elements found in the vimentin gene. The degree of the suppression was greater in 3T3-Hras than in Ltk- cells. These positive and negative regulatory elements may be differentially involved in the regulation of ME491 antigen expression depending on the cell type.

Indexed as

Gene Expression Regulation, NeoplasticIntronsPromoter Regions, GeneticSuppression, Genetic3T3 CellsAnimalsAntigens, CDAntigens, NeoplasmBase SequenceBinding SitesChloramphenicol O-AcetyltransferaseEnhancer Elements, GeneticGenes, rasHumansMelanomaMiceAntigens, CDAntigens, NeoplasmCD63 protein, humanCd63 protein, mouseChloramphenicol O-AcetyltransferaseOligodeoxyribonucleotidesPlatelet Membrane GlycoproteinsRecombinant ProteinsRepressor ProteinsTetraspanin 30Transcription Factors

Identifiers

PMID1752782
PMCPMC5918325
OpenAlexW2088402935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.